CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its fourth quarter and full year 2022 financial results on March 16, 2023, after market close. A conference call and webcast are scheduled for that day at 4:30 p.m. EDT, featuring CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Interested participants can join the call via domestic and international lines. A replay will also be available on the company's website for those unable to attend live. Co-Diagnostics specializes in molecular diagnostics and offers innovative technology for nucleic acid analysis.
- Scheduled earnings release may provide insight into financial performance and future guidance.
- None.
SALT LAKE CITY, March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors.
Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The call and webcast will be available via:
Webcast: | ir.codiagnostics.com on the Events & Webcasts page |
Conference Call: | 844-481-2661 (domestic) or 412-317-0652 (international) |
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2022-earnings-release-date-and-webcast-301767660.html
SOURCE Co-Diagnostics
FAQ
When will Co-Diagnostics release its fourth quarter and full year 2022 financial results?
What time is the Co-Diagnostics earnings call?
How can I access the Co-Diagnostics earnings call?
Will there be a recording of the Co-Diagnostics earnings call?
Who will be presenting during the Co-Diagnostics earnings call?
